Catch up with what Optometry Times shared this week:

EyePoint Pharmaceuticals falls short of primary endpoint for Phase 2 PAVIA Trial for NPDR

By Jordana Joy

EyePoint Pharmaceuticals announced that its Phase 2 PAVIA trial fell short of achieving its primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, or approximately 9 months, after the DURAVYU injection. However, EyePoint did report that DURAVYU demonstrated stable or improved disease severity with reduced rates of NPDR in 9 months, as well as displayed a favorable safety and tolerability profile with no drug-related serious adverse events, according to a release. Additionally, no cases of endophthalmitis or retinal vasculitis were observed.

DURAVYU, previously known as and conditionally accepted by the FDA as EYO-1901, is a tyrosine kinase inhibitor and was administered to study participants in 2 doses as an intravitreal insert in the multicenter, prospective, double-masked, parallel trial. FDA approval, along with its timeline for potential approval, is uncertain at this time, the release said.

Read here...

Lumibird Medical announces launch of dry eye diagnostic aid

By Jordana Joy

Lumibird Medical, a medical division of Lumibird Group, has announced the launch of the C.DIAG, an autonomic dry eye diagnostic aid platform that utilizes artificial intelligence (AI) algorithms. According to a news release, the new diagnostic aid brings with it a new component of the company’s C.SUITE platform, which allows healthcare professionals to diagnose, treat, and educate dry eye patients.

The release stated that the demand for diagnostic tools stems from the management of dry eye disease’s (DED) tendency to complicate the treatment of glaucoma, refractive and cataract surgeries, and contact lenses, among others.

Read here...

Investigators detail correlation between visual markers and neurological deficits in mouse model of MS

By Lynda Charters

Investigators who developed an experimental murine model of autoimmune encephalomyelitis found a significant correlation between visual function and structure and overall motor-sensory impairment, according to Oliver W. Gramlich, PhD, who presented the findings of his research team at the Association for Research in Vision and Ophthalmology annual meeting in Seattle. He is from the Department of Ophthalmology, University of Iowa Hospitals and Clinics, and the Iowa City VA Medical Center, Iowa City, IA.

The first symptom in from one quarter to almost half of patients with multiple sclerosis (MS) is acute optic neuritis. With progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG).

Read here...

CHAMP Phase 3 trial finds myopia controlled by low-dose atropine 0.01% over 4-year course

By Lynda Charters

A recent study found 2 noteworthy outcomes: NVK002 (low-dose atropine 0.01%, Vyluma Inc.) maintained myopia control during a fourth year of dosing and discontinuation did not cause rebound myopia progression, according to first author Karla Zadnik, OD, PhD, from Ohio State University, Columbus. She presented her results1 at the Association for Research in Vision and Ophthalmology annual meeting in Seattle.

In this study, stage 2 of the CHAMP phase 3 trial investigated the effect of continued dosing of the drug for an additional 12 months on the control of myopia as well as the development of myopia rebound when the dosing was discontinued. In the previous stage 1 of the phase 3 CHAMP trial, the results indicated that more children treated with the atropine 0.01% dose had less than a half dioptre (D) increase in spherical equivalent refraction (SER) over the course of 3 years.

Read here...

Evaluating in-home use of novel contact lens solution in potential lens dropouts

By Marjorie Rah, OD, PhD, FAAO; Emily Kaiser Maharjan

At ARVO 2024, Marjorie Rah, OD, PhD, FAAO, presented a poster on an in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) to measure increased comfort for contact lens wearers. This test was limited to patients who self-reported consideration of discontinuing lens wear in the 6 months following the initial appointment. Only patients who reported dryness as a factor for discontinuation were considered.

Of the 202 participants, 90% of patients reported improved comfort following the switch to the new multipurpose solution, and 86.6% agreed they are more likely to continue contact lens wear following the study. These findings were self-reported in a survey completed by patients.

Watch here...